Reviewer's report

Title: Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome

Version: 2 Date: 1 August 2011

Reviewer: Claudio Viscoli

Reviewer's report:

The bottom line is that in my opinion the following manuscript is now suitable for publication. The Authors have answered all questions in a satisfying way. The English is good and the statistical revision appropriate. The article is certainly of importance in its field.

Conflict on interest:

Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this paper, either now or in the future?

I have received speaker's fees from several companies involved in antifungals, including Pfizer, Astellas, Gilead, MSD.

- Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper, either now or in the future?

The answer is NO

- Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

The answer is NO

- Do you have any other financial competing interests?

The answer is NO
- Do you have any non-financial competing interests in relation to this paper?
The answer is NO